Levetiracetam Tablet
Product Images NDC 43063-499

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 43063-499). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

43063499 Label (43063499)

Levetiracetam USP 500 mg oral tablet label from PD-Rx Pharmaceuticals, Inc. The label includes the NDC number 43063-499-60 and states the package contains 60 tablets. Prescription only with a warning to keep out of reach of children and instructions to see package insert for dosage and storage. The label displays reorder number 103345, lot number 119B19, and expiration date 09/2021. It also provides FDA side effect reporting information and dosage instructions in English and Spanish.*

FDA Label Image

Ectdmodule1usa1

Chemical structure of the active ingredient levetiracetam showing molecular connectivity with a pyrrolidone ring and functional groups including an amide and an ethyl side chain.*

FDA Label Image

Ectdmodule1usa2

A bar chart comparing the percentage of patients among three groups: placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The chart shows increasing patient percentages from placebo to the higher Levetiracetam doses, with values approximately 7.4% for placebo, 37.1% for 1000 mg/day, and 39.6% for 3000 mg/day.*

FDA Label Image

Ectdmodule1usa3

A bar chart showing the percentage of patients for three groups: placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day. The y-axis represents the percentage of patients, with values around 6.3% for placebo, 20.8% for 1000 mg/day, and 35.2% for 2000 mg/day, indicating comparative patient response rates.*

FDA Label Image

Ectdmodule1usa4

Bar chart showing percentage of patients responding to Placebo versus Levetiracetam 3000 mg/day. The chart compares response rates: 14.4% for Placebo (N=104) and 39.4% for Levetiracetam (N=180).*

FDA Label Image

Ectdmodule1usa5

A bar chart comparing the percentage of patients between two groups: Placebo (N=97) with 19.6% and Levetiracetam (N=101) with 44.6%. The y-axis represents the percentage of patients from 0% to 45%.*

FDA Label Image

Ectdmodule1usa6

A bar chart comparing the percentage of patients between two groups: Placebo (51 patients) and Levetiracetam (58 patients). The Placebo group shows approximately 19.6% of patients, while the Levetiracetam group shows approximately 43.1% of patients. The vertical axis represents the percentage of patients up to 45%.*

FDA Label Image

Ectdmodule1usa7

A bar chart comparing the percentage of patients between placebo and Levetiracetam groups. The chart shows approximately 45.2% of patients for placebo (N=84) and 72.2% for Levetiracetam (N=79). The y-axis represents the percentage of patients from 0% to 100%.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.